Levis MJ - Search Results

1

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP. Smith CC, et al. Among authors: levis mj. Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016. Nature. 2012. PMID: 22504184 Free PMC article.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

Novel FLT3 tyrosine kinase inhibitors.

Levis M, Small D. Levis M, et al. Expert Opin Investig Drugs. 2003 Dec;12(12):1951-62. doi: 10.1517/13543784.12.12.1951. Expert Opin Investig Drugs. 2003. PMID: 14640939 Review.

4

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.

Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Brown P, et al. Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27. Blood. 2004. PMID: 15166029 Free article.

5

FLT3/ITD mutation signaling includes suppression of SHP-1.

Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D. Chen P, et al. J Biol Chem. 2005 Feb 18;280(7):5361-9. doi: 10.1074/jbc.M411974200. Epub 2004 Dec 1. J Biol Chem. 2005. PMID: 15574429 Free article.

6

FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells.

Li L, Piloto O, Kim KT, Ye Z, Nguyen HB, Yu X, Levis M, Cheng L, Small D. Li L, et al. Br J Haematol. 2007 Apr;137(1):64-75. doi: 10.1111/j.1365-2141.2007.06525.x. Br J Haematol. 2007. PMID: 17359372 Free article.

7

FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.

Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, Levis MJ, Neckers L, Trepel JB. Kajiguchi T, et al. Among authors: levis mj. Leukemia. 2007 Dec;21(12):2476-84. doi: 10.1038/sj.leu.2404923. Epub 2007 Sep 13. Leukemia. 2007. PMID: 17851558

8

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Pratz K, Levis M. Pratz K, et al. Leuk Lymphoma. 2008 May;49(5):852-63. doi: 10.1080/10428190801895352. Leuk Lymphoma. 2008. PMID: 18452067 Free PMC article. Review.

9

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS. Zarrinkar PP, et al. Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4. Blood. 2009. PMID: 19654408 Free PMC article.

10

Bench to bedside targeting of FLT3 in acute leukemia.

Pratz KW, Levis MJ. Pratz KW, et al. Among authors: levis mj. Curr Drug Targets. 2010 Jul;11(7):781-9. doi: 10.2174/138945010791320782. Curr Drug Targets. 2010. PMID: 20370649 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters